Naimish Patel - 28 May 2024 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Medical Officer
Signature
/s/ AJ Silver, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
28 May 2024
Net transactions value
$0
Form type
4
Filing time
29 May 2024, 16:15:03 UTC
Next filing
18 Oct 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Award $0 +85,000 $0.000000 85,000 28 May 2024 Common Shares 85,000 $54.84 Direct F1
transaction CRSP Restricted Stock Units Award $0 +40,000 $0.000000 40,000 28 May 2024 Common Shares 40,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on May 28, 2024 with respect to 85,000 Common Shares. 25% of the shares shall vest on May 28, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3 This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028.